Vericel Corporation or MiMedx Group, Inc.: Who Leads in Yearly Revenue?

Biotech Battle: Vericel vs. MiMedx in Revenue Growth

__timestamp	MiMedx Group, Inc.	Vericel Corporation
Wednesday, January 1, 2014	118223000	28796000
Thursday, January 1, 2015	187296000	51168000
Friday, January 1, 2016	245015000	54383000
Sunday, January 1, 2017	321139000	63924000
Monday, January 1, 2018	359111000	90857000
Tuesday, January 1, 2019	299255000	117850000
Wednesday, January 1, 2020	248234000	124179000
Friday, January 1, 2021	258615000	156184000
Saturday, January 1, 2022	267841000	164365000
Sunday, January 1, 2023	321477000	197516000

Igniting the spark of knowledge

A Tale of Two Innovators: Vericel Corporation vs. MiMedx Group, Inc.

In the dynamic world of biotechnology, Vericel Corporation and MiMedx Group, Inc. have emerged as key players. Over the past decade, MiMedx has consistently outpaced Vericel in annual revenue, boasting a 2023 revenue that is approximately 63% higher than Vericel's. However, Vericel has shown remarkable growth, with its revenue increasing nearly sevenfold since 2014. This growth trajectory suggests a promising future for Vericel as it narrows the gap with MiMedx.

From 2014 to 2023, MiMedx's revenue grew by 172%, while Vericel's surged by 585%. This impressive growth for Vericel highlights its potential to challenge MiMedx's dominance. As both companies continue to innovate, investors and industry watchers should keep a close eye on their evolving strategies and market positions.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025